Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 628-636
DOI: 10.1016/j.jcf.2026.03.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Andrea Gramegna und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione I…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Indoles, Quinolones. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lombardy Region, Ministry of Health, Ministero dell'Università e della Ricerca.
Abstract (Originalsprache)
BACKGROUND: Limited evidence exists to guide Elexacaftor-Tezacaftor-Ivacaftor (ETI) use in adults with cystic fibrosis (awCF) and preserved lung function (ppFEV1 >90%). To address the resulting variability in prescribing practices, we conducted a European survey among a group of adult CF centres aiming at identifying factors influencing ETI initiation decisions in adults with preserved lung function. METHODS: Between April and June 2024, we invited 25 ECFS prescribers from 25 adult CF centres to participate in a web-based survey to explore factors influencing ETI initiation in adults with CF and ppFEV₁ >90%. The survey questionnaire collected data on centre characteristics, prescribing ETI attitudes, and the impact of specific clinical variables on ETI prescription decision in this subgroup. RESULTS: Twenty-three CF specialists (92%) responded. Most specialists (69.6%) favoured early treatment initiation in all eligible patients. A key factors influencing ETI initiation decisions was the presence of respiratory symptoms. In adults with preserved lung function, however, microbiological and imaging features emerged as the most influential factors driving treatment decision. While patient willingness and symptoms strongly encouraged ETI use, factors like age over 50, a history of mental health issues, and pregnancy desire resulted in conflicting prescribing attitudes among centers. CONCLUSIONS: Although several disease markers more consistently support the decision to initiate ETI in individuals with preserved lung function, the absence of clear clinical guidance contributes to heterogeneous prescribing practices across centres. This highlights the need for longitudinal studies to clarify the long-term outcomes of ETI in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: chiara.premuda@policlinico.mi.it.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Mother and Child Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
- Pulmonology Department, Unidade de Saúde Local S.João, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal.
- Cystic Fibrosis Centre, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal; Faculdade de Medicina, Centro Académico Universitário de Lisboa, Lisboa, Portugal.
Förderung
- Lombardy Region
- Ministry of Health
- Ministero dell'Università e della Ricerca
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Gramegna, A., Magnoni, C., Premuda, C., Alicandro, G., Akkerman, O., Amorim, A., Azevedo, P., Bourke, S., Carnovale, V., Diamantea, F., Fila, L., Frost, F., Giron Moreno, R. M., Pescaru, C., Polverino, E., Felipe Montiel, A., Rachel, M., Stoyanova, G. P., Van Braeckel, E., …, & Blasi, F. (2026). Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey. Journal of Cystic Fibrosis, 25(4), 628-636. https://doi.org/10.1016/j.jcf.2026.03.005
Vancouver
Gramegna A, Magnoni C, Premuda C, Alicandro G, Akkerman O, Amorim A, et al. Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey. Journal of Cystic Fibrosis. 2026;25(4):628-636. doi:10.1016/j.jcf.2026.03.005
BibTeX
@article{Gramegna2026,
author = {Gramegna, Andrea and Magnoni, Carlo and Premuda, Chiara and Alicandro, Gianfranco and Akkerman, Onno and Amorim, Adelina and Azevedo, Pilar and Bourke, Stephen and Carnovale, Vincenzo and Diamantea, Filia and Fila, Libor and Frost, Freddy and Giron Moreno, Rosa Maria and Pescaru, Camelia and Polverino, Eva and Felipe Montiel, Almudena and Rachel, Marta and Stoyanova, Gergana Petrova and Van Braeckel, Eva and Volpi, Sonia and Vukić-Dugac, Andrea and Wege, Sabine and Simmonds, Nicholas J and Plant, Barry J and Downey, Damian G and van Koningsbruggen-Rietschel, Silke and Burgel, Pierre-Régis and Blasi, Francesco},
title = {Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {628--636},
doi = {10.1016/j.jcf.2026.03.005}
}
EUVIMED